SAN FRANCISCO ( TheStreet) -- Celgene ( CELG) was a big winner on the first day of the J.P. Morgan Healthcare Conference. The big-cap biotech is the traditional kick-off presentation at this closely followed conference, and this year, the company set a high bar for its competitors with strong financial guidance (including a bullish 2017 forecast for the first time) and positive psoriasis results from studies involving its experimental drug apremilast. Celgene shares rose more than 4% to $85.73 on Monday and the stock was up again in Tuesday's pre-market session, bolstered by some analyst upgrades. Gilead Sciences ( GILD) and Biogen Idec ( BIIB) also presented at the J.P. Morgan conference on Monday. While both offered confident outlooks for the coming year, Celgene was a standout. Amgen ( AMGN) presents at the conference later today. Read a lot more about Celgene's outlook and the way investors and others reacted to the company's J.P. Morgan presentation on Twitter with this Appeering conversation thread: -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.